Autopsy report · NCT00311766

A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

“Lack of patient availability and expiration of study drug”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 6 years 9 months before it stopped.
• 30 participants enrolled.
• Results were posted on the registry 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

RegeneRx Biopharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Epidermolysis Bullosa

Interventions

Thymosin Beta 4; Placebo

Participants

30

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.